VivoSeq
Nephrology

Kidney Transplant

376

Pipeline Programs↗

100

Active Trials↗

94

Companies Involved↗

Kidney Transplant is a highly competitive landscape with 376 programs across 94 companies. The most active players are Iovance Biotherapeutics, Inc., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Jiangsu Topcel-KH Pharmaceutical Co., Ltd.. 103 therapies are approved with 70 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

91/100

Pipeline Velocity

52/100

Mech. Concentration

4/100

Completion Rate

77/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1S

Shanghai Simnova Biotechnology Co.,Ltd.

1 program

Phase 1Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

2 programs

Phase 1E

Eledon Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

363 of 426 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody256%Vaccine154%Protein / enzyme123%Cell therapy61%Peptide3<1%RNA therapy1<1%Other1<1%

Small molecule leads; the ring shows all 426 classified programs, each share of the total. Modality classified for 100% of 477 pipeline programs.

Analysis

Trial Status

583

clinical trials

Completed320 · 55%
Unknown status67 · 11%
Terminated66 · 11%
Recruiting53 · 9%
Withdrawn27 · 5%
Not yet recruiting25 · 4%
Other25 · 4%

Clinical Trials

Trial Activity

583 trials

Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
Recruiting·UUniversity of Erlangen-Nürnberg Medical School·Phase 4·NCT06560801·48 enrolled
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
Recruiting·HHansa Biopharma AB·Phase 2·NCT05753930·10 enrolled
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
Recruiting·HHospices Civils de Lyon·N/A·NCT03955172·20 enrolled
Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study
Recruiting·QQianfoshan Hospital·Phase 1·NCT07045467·30 enrolled
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
Recruiting·MMassachusetts General Hospital·Phase 4·NCT06751992·92 enrolled
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
Recruiting·SShahid Beheshti University of Medical Sciences·Phase 4·NCT07423247·30 enrolled
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Recruiting·NNational Taiwan University Hospital·N/A·NCT07294547·80 enrolled
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05938712·20 enrolled
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 3·NCT06832410·10 enrolled
Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program
Recruiting·VVirginia Commonwealth University·N/A·NCT06688825·30 enrolled
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06056102·20 enrolled
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06830798·450 enrolled
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
Recruiting·ZZhejiang University·Phase 1·NCT06769191·20 enrolled
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT06059664·150 enrolled
Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch
Recruiting·UUniversity Hospital, Antwerp·Phase 4·NCT06493526·20 enrolled
Page 1 of 39

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)